Literature DB >> 2692012

Visual hallucinations in the elderly associated with the use of levodopa.

A K Banerjee1, P G Falkai, M Savidge.   

Abstract

Visual hallucinations are a well recognized unwanted effect of treatment with levodopa. Although many individual cases have been reported, there has only been one review previously published about this finding, and this did not discriminate age groups. We present five cases and briefly review the literature. It is important to enquire specifically about visual hallucinations in patients on levodopa therapy at follow up, as this otherwise potentially reversible side effect may be overlooked.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2692012      PMCID: PMC2429337          DOI: 10.1136/pgmj.65.764.358

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  16 in total

1.  L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients.

Authors:  J M Rabey; J Vardi; J J Askenazi; M Streifler
Journal:  Gerontology       Date:  1977       Impact factor: 5.140

2.  Mental symptoms in Parkinson's disease during chronic treatment with levodopa.

Authors:  R D Sweet; F H McDowell; J S Feigenson; A W Loranger; H Goodell
Journal:  Neurology       Date:  1976-04       Impact factor: 9.910

3.  Effects of L-dopa in patients with dementia.

Authors:  O W Sacks; C Messeloff; W Schartz; A Goldfarb; M Kohl
Journal:  Lancet       Date:  1970-06-06       Impact factor: 79.321

4.  Drugs for Parkinson's disease.

Authors:  F I Caird; J Williamson
Journal:  Lancet       Date:  1978-05-06       Impact factor: 79.321

5.  Letter: Bromocriptine in parkinsonism.

Authors:  A G Debono; I Donaldson; C D Marsden; J D Parkes
Journal:  Lancet       Date:  1975-11-15       Impact factor: 79.321

6.  Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.

Authors:  H L Klawans; W J Weiner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

7.  Levodopa-induced psychosis: a kindling phenomenon.

Authors:  C Moskovitz; H Moses; H L Klawans
Journal:  Am J Psychiatry       Date:  1978-06       Impact factor: 18.112

8.  Bromocriptine in parkinsonism. A long-term study.

Authors:  A J Lees; S Haddad; K M Shaw; L J Kohout; G M Stern
Journal:  Arch Neurol       Date:  1978-08

9.  Psychiatric aspects in Parkinsonism treated with L-dopa.

Authors:  A R Damãsio; J Lobo-Antunes; C Macedo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-10       Impact factor: 10.154

10.  Inappropriate prescribing in the elderly.

Authors:  K R Adams; S Al-Hamouz; E Edmund; R C Tallis; C Vellodi; M Lye
Journal:  J R Coll Physicians Lond       Date:  1987-01
View more
  5 in total

1.  Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

Authors:  A Moser; F Siebecker; P Vieregge; P Jaskowski; D Kömpf
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Behavioral impairments and serotonin reductions in rats after chronic L-dopa.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

Review 3.  Cerebral correlates of psychotic syndromes in neurodegenerative diseases.

Authors:  Kurt A Jellinger
Journal:  J Cell Mol Med       Date:  2012-05       Impact factor: 5.310

Review 4.  Approach to Cognitive Impairment in Parkinson's Disease.

Authors:  Qiang Zhang; Georgina M Aldridge; Nandakumar S Narayanan; Steven W Anderson; Ergun Y Uc
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 6.088

Review 5.  L-Dopa and Brain Serotonin System Dysfunction.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Toxics       Date:  2015-03-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.